Q/C Technologies, Inc. (QCLS) — SEC Filings

Q/C Technologies, Inc. (QCLS) — 45 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 25 8-K, 6 10-Q, 4 DEF 14A.

View Q/C Technologies, Inc. on SEC EDGAR

Overview

Q/C Technologies, Inc. (QCLS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: Q/C Technologies, Inc. (QCLS) reported a net loss of $5,732,326 for the nine months ended September 30, 2025, a significant improvement from the $21,295,080 net loss in the same period of 2024. The company's cash position dramatically increased to $6,904,185 as of September 30, 2025, up from $173,15

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Q/C Technologies, Inc. is neutral.

Filing Type Overview

Q/C Technologies, Inc. (QCLS) has filed 25 8-K, 6 10-Q, 4 DEF 14A, 4 8-K/A, 2 10-K, 2 SC 13G/A, 1 SC 13D, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (45)

Q/C Technologies, Inc. SEC Filing History
DateFormDescriptionRisk
Dec 9, 20258-K8-K Filing
Nov 19, 202510-QQCLS Cash Surges on New Capital, Net Loss Narrows to $5.7Mhigh
Nov 14, 20258-KQ/C Technologies Files 8-K: Officer/Director Changes & Shareholder Votesmedium
Oct 20, 2025DEF 14AQCLS Seeks Shareholder Nod for Dilutive Issuances, Reverse Splithigh
Oct 6, 20258-K/AQ/C Technologies Files 8-K/A Amendmentlow
Oct 3, 20258-KQ/C Technologies, Inc. Files 8-K: Material Agreements & Equity Changesmedium
Sep 26, 20258-KQ/C Technologies Files 8-K with Bylaw Amendmentslow
Sep 10, 20258-KTNF Pharmaceuticals Files 8-K: Material Agreement & Bylaw Changesmedium
Sep 5, 20258-K/ATNF Pharmaceuticals Files 8-K/A Amendmentlow
Sep 2, 20258-KTNF Pharmaceuticals Announces Material Agreements & Officer Changesmedium
Aug 19, 202510-QTNF Pharmaceuticals Files Q2 2025 10-Qmedium
Jun 6, 20258-KTNF Pharmaceuticals Holds Shareholder Vote on Reverse Splitmedium
May 15, 202510-QTNF Pharmaceuticals Files Q1 2025 10-Qmedium
May 9, 20258-KTNF Pharmaceuticals Files 8-K for Bylaw Amendments & Exhibitslow
Apr 21, 2025DEF 14ATNF Pharmaceuticals Files 2024 DEF 14Amedium
Apr 11, 202510-KTNF Pharmaceuticals Files 2024 10-K, Details Preferred Stockmedium
Mar 21, 20258-KTNF Pharmaceuticals Faces Delisting Concernshigh
Mar 10, 20258-KTNF Pharmaceuticals Files 8-K Reportlow
Nov 26, 20248-KTNF Pharmaceuticals Files 8-K: Director Changes & Moremedium
Nov 14, 2024SC 13G/ASC 13G/A Filing

Risk Profile

Risk Assessment: Of QCLS's 41 recent filings, 3 were flagged as high-risk, 26 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Q/C Technologies, Inc. Financial Summary (10-Q, Nov 19, 2025)
MetricValue
Revenue$0
Net Income-$5,732,326
EPSN/A
Debt-to-EquityN/A
Cash Position$6,904,185
Operating MarginN/A
Total Assets$37,231,786
Total DebtN/A

Key Executives

  • Joshua Silverman
  • James Altucher
  • Dr. Jonathan L. Cohen

Industry Context

Q/C Technologies operates in a sector that often requires substantial upfront investment in research and development to bring innovative products to market. Companies in this space frequently rely on external financing, including venture capital and equity issuances, to fund operations until revenue streams are established. The competitive landscape is characterized by rapid technological advancements and the need for continuous innovation.

Top Tags

corporate-governance (14) · material-agreement (7) · financials (7) · 10-Q (5) · corporate-action (5) · amendment (4) · officer-changes (3) · filing-update (3) · exhibits (3) · equity-sale (3)

Key Numbers

Q/C Technologies, Inc. Key Metrics
MetricValueContext
Cash$6.90MIncreased from $0.17M at Dec 31, 2024, a 3899% increase, primarily from financing activities.
Net Loss$5.73MReduced from $21.30M in the prior year period, a 73% improvement.
Total Assets$37.23MIncreased from $21.42M at Dec 31, 2024, driven by a new technology license.
Total Liabilities$15.91MIncreased from $6.70M at Dec 31, 2024, due to contingent consideration and derivative liabilities.
Technology License$14.09MNew non-current asset acquired during the nine months ended September 30, 2025.
Net Cash Provided by Financing Activities$9.35MPrimary source of cash increase for the nine months ended September 30, 2025.
Research and Development Expenses$2.78MIncreased from $2.31M in the prior year, indicating continued investment.
Product Revenue0No product revenue reported for the three or nine months ended September 30, 2025 or 2024.
Minimum percentage of common stock outstanding20%Threshold for Nasdaq Listing Rule 5635(d) approval for new issuances
Additional shares for Equity Incentive Plan1,375,000Increase in shares authorized under the 2021 Equity Incentive Plan
Total shares for Equity Incentive Plan1,400,000New total shares authorized under the 2021 Equity Incentive Plan after amendment
Reverse stock split ratio range1-for-2 to 1-for-250Discretionary range for the Board to effect a reverse stock split
Special Meeting Date and Time2025-11-10T10:00:00ZDate and time of the virtual Special Meeting of Stockholders
Record Date2025-09-18T00:00:00ZDate for determining stockholders entitled to vote at the Special Meeting
Par value per share$0.001Par value for Common Stock, Series H Preferred Stock, and Series I Preferred Stock

Related Companies

MYMD · PMCB

Frequently Asked Questions

What are the latest SEC filings for Q/C Technologies, Inc. (QCLS)?

Q/C Technologies, Inc. has 45 recent SEC filings from Feb 2024 to Dec 2025, including 25 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of QCLS filings?

Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Q/C Technologies, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Q/C Technologies, Inc. (QCLS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Q/C Technologies, Inc.?

Key financial highlights from Q/C Technologies, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for QCLS?

The investment thesis for QCLS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Q/C Technologies, Inc.?

Key executives identified across Q/C Technologies, Inc.'s filings include Joshua Silverman, James Altucher, Dr. Jonathan L. Cohen.

What are the main risk factors for Q/C Technologies, Inc. stock?

Of QCLS's 41 assessed filings, 3 were flagged high-risk, 26 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Q/C Technologies, Inc.?

Forward guidance and predictions for Q/C Technologies, Inc. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.